29.12 USD
▲+0.12+3.30%
盘后 28.13 -0.21%
2026-08-03
市值
$2.00B
市盈率
—
EPS
-0.91
股息率
—
52 周区间
11.32 – 31.00
成交量
632.27K
Beta
1.29
目标价
40.00
52W 低 11.3252W 高 31.00
价格走势
公司简介
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology tr...